HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
[Taipei, Shanghai, San Francisco | May 26, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026.
The offering attracted strong interest from domestic and international institutional investors and was oversubscribed. As part of the offering, HanchorBio introduced OrbiMed, a leading global healthcare investment firm, as a strategic investor. OrbiMed’s participation represents an important example of overseas institutional investment in Taiwan’s innovative drug development sector and reflects growing international interest in HanchorBio’s technology platform and clinical-stage pipeline.
HanchorBio issued 9.4 million new common shares in its pre-listing capital increase. Of these, 10% were reserved for employee subscription, while the remaining 8.46 million shares were offered through bookbuilding. Cathay Securities served as the lead underwriter. The bookbuilding process was conducted from May 15 to May 19, with an indicative price range of NT$110 to NT$130 per share. Supported by strong demand from institutional and professional investors, the final underwriting price was set at NT$120 per share.
HanchorBio said its IPO structure reflects a disciplined approach to financing and capital market planning. The company released approximately 6% of its listed share capital in this offering, taking into account its current funding position and the objective of limiting unnecessary dilution to existing shareholders. The bookbuilding process also enabled HanchorBio to broaden its shareholder base by introducing long-term institutional and strategic investors ahead of its public market debut.
OrbiMed is a global healthcare investment firm with investments across biopharmaceuticals, medical devices, diagnostics, digital health, healthcare services, and healthcare technology.
HanchorBio noted that OrbiMed’s participation underscores external recognition of the company’s FBDB™ fusion protein platform and clinical-stage pipeline. The company plans to continue advancing discussions on global partnerships with pharmaceutical companies and strategic collaborators.
Following the completion of this financing round, HanchorBio’s financial position is further strengthened. The company currently has approximately US$140 million in cash and available bank credit facilities, equivalent to approximately NT$4.5 billion. HanchorBio expects its existing resources to support the advancement of clinical trials, process development, and global business development activities for its core assets over the coming years.
Founded in 2020, HanchorBio has built an integrated operating model spanning early-stage research, process development, and clinical development. Supported by its proprietary FBDB™ platform and an international management team, the company is advancing a pipeline of next-generation immunotherapies for oncology and autoimmune diseases.
Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, said, “The global pharmaceutical industry is entering a period of significant portfolio renewal, as a number of major blockbuster medicines, including Keytruda, are expected to face patent expirations in the coming years. As large pharmaceutical companies increasingly seek external innovation to address future portfolio needs, we believe HanchorBio’s platform and clinical programs are well-positioned for continued global engagement. We will continue advancing its clinical and business development strategies to create long-term value for shareholders.”
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.
漢康-KY引進國際策略投資人奧博資本入股
5月29日創新板掛牌 詢圈超額認購
專注創新藥物開發的漢康-KY（股票代碼：7827）初次上市普通股股票（IPO）詢價圈購承銷作業於今（26）日圓滿完成。本次募資案獲國內外機構投資人高度關注與踴躍認購，更成功引進管理規模逾百億美元的全球頂尖醫療健康基金—奧博資本（OrbiMed）策略性入股。此舉不僅彰顯國際資本對漢康-KY技術價值與臨床潛力的實質肯定，亦為台灣生技資本市場的國際化進程注入新動能。
漢康-KY 本次辦理上市前現金增資發行新股 9,400 張。其中保留10%由員工認購，其餘 8,460張全數採詢價圈購方式辦理，主辦承銷商為國泰證券。詢圈作業自5月15日展開至19 日截止，詢圈參考價區間為新台幣110至130元，吸引眾多國內外機構法人及專業投資人熱烈參與，在投資人超額認購的強勁需求驅動下，最終承銷價定於120元，公司預計5月29日正式掛牌創新板。
針對本次IPO的發行架構與承銷模式，漢康-KY展現三大嚴謹的財務規劃與資本市場策略考量。首先，精準募資避免股權稀釋；本次上市僅釋出約6%的掛牌股數，係因公司目前營運資金充裕，此舉能有效避免過度稀釋現有籌碼，保障既有股東權益，同時展現經營團隊對公司未來企業估值持續看漲的強烈信心。
其次，優化股權結構，奠定長期價值；詢圈可引進認同公司長期發展價值的國際專業機構及策略投資人，能有效避免籌碼過度分散或短線投機資金進出，為後續研發與資本市場深度發展奠定穩健基礎。第三，實現定價效率，穩定市場籌碼；透過特定期間內精準探詢法人認購意願，不僅落實資本市場的價格發現功能，亦顯著降低市場情緒波動引發的短期價格震盪，有利於掛牌後的籌碼穩定。
本次引進的奧博資本是全球知名的醫療健康投資機構，投資領域遍及生物製藥、醫療器材、診斷、數位健康、醫療照護及服務科技等，旗下管理的全球資產超過170億美元，投資階段涵蓋早期新創、成長型企業至大型上市公司等。其過往核心投資組合堪稱全球生技風向球，包括多間國際一線企業。
漢康-KY指出，奧博資本投資台灣創新藥企的案例在市場上相對罕見，本次參與公司的詢圈入股，再次凸顯核心融合蛋白平台FBDB™與臨床產品線具備高度的國際市場潛力，未來也將持續加速與國際藥廠及策略夥伴的合作布局。
在完成本輪募資後，漢康-KY的財務結構與現金部位愈加強韌。目前公司帳上現金及銀行授信額度合計高達近1.4億美元（折合新台幣約45億元），現有資金水位極其充沛，足以充裕支應未來數年內多項核心資產的臨床試驗推進、製程優化及全球商務授權活動。
漢康-KY成立於2020年，憑藉高度自主研發的FBDB™核心技術平台與國際專業經營團隊，打造出從早期研發、製程開發到臨床試驗的一站式高效營運模式。產品線聚焦於次世代免疫療法的雙軌發展，同步推進廣譜抗癌藥物與自體免疫疾病藥物。
董事長劉世高強調，未來數年全球製藥史上將迎來一波大規模的專利斷崖（Patent Cliff）潮，如Keytruda等年銷售達數百億美元的重磅明星藥物專利將陸續到期。國際藥廠為了填補專利過期後的營收缺口，正積極尋求外部藥品技術授權來豐富產品線。漢康-KY具備的核心競爭力已成功進入國際藥界的核心視野，隨著各項臨床數據的陸續推進，公司將持續釋放龐大的國際授權與商業價值，為股東創造最大利益。
關於漢康-KY：
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康-KY”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDB多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康-KY的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。